This Slide: #30 of 100 |
Slide #30. Mallinckrodt — Cadence Pharmaceuticals, Inc.
Acquirer:
Mallinckrodt (MNK)
Acquiree:
Cadence Pharmaceuticals, Inc. (CADX)
Details:
Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.
Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.
Open the MNK Page at The Online Investor »
Mallinckrodt develops, manufactures, and markets pharmaceutical products and diagnostic imaging agents. Co. focuses on the manufacturing of pain management medications. Co provides its products to several wholesalers and retail drug store chains.
Open the CADX Page at The Online Investor »
|
|
Free Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |